Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biogen : plunges 30% after FDA panel votes against Alzheimer's drug

11/09/2020 | 08:21am EST
FILE PHOTO: A sign marks a Biogen facility in Cambridge

(Reuters) - Biogen Inc's shares slumped about 30% on Monday as the drugmaker's chances of getting a regulatory approval for its experiment Alzheimer's treatment suffered a blow after a panel of experts to the U.S. Food and Drug Administration voted against the medicine.

Wall Street analysts largely believe the panel's near-unanimous votes against the drug, aducanumab, make it difficult for the FDA to go against the panel.

"Approving aducanumab, in the face of such an overwhelmingly negative vote and commentary, is virtually impossible and would destroy the agency's reputation at a very tenuous time for the regulator, ahead of potential actions on COVID vaccines," Baird analyst Brian Skorney said.

The panel on Friday voted "no" to three questions related to whether a single successful large trial of the drug was enough evidence of its effectiveness, given the failure of a second large study.

The FDA is expected to make its decision on aducanumab by March and is not obligated to follow the recommendations of the panel, but usually does.

It is uncommon for the FDA to act against the committee, Jefferies analyst Michael Yee said, adding that it happens less than 20% of the time.

Bowing to pressure from patient advocates, the agency in 2016 approved a treatment for Duchenne muscular dystrophy from Sarepta Therapeutics Inc, even though an outside panel
of experts and the agency's own reviewers questioned the drug's efficacy. (https://reut.rs/2IaXM17)

"The FDA can do what it wants," Stifel analyst Paul Matteis said, adding that the vote against Sarepta's Exondys 51 was obviously better than the 0-10-1 against aducanumab.

If approved, aducanumab would become the first new treatment for Alzheimer's in decades and the first that appears to be able to slow progression of the fatal, mind-wasting condition, potentially bringing in billions of dollars in sales for Biogen.

(Reporting by Manas Mishra and Manojna Maddipatla in Bengaluru; Editing by Shounak Dasgupta)

ę Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. -2.89% 242.9 Delayed Quote.-0.80%
SAREPTA THERAPEUTICS, INC. -1.68% 79.62 Delayed Quote.-53.30%
All news about BIOGEN INC.
11/22Biogen's Alzheimer's Drug Reportedly Caused Brain Swelling in Over One-Third of Patient..
11/22Study Shows Biogen's Alzheimer's Drug Reportedly Shows Brain Swelling in 35% of Patient..
11/22BIOGEN : Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormaliti..
11/19RBC Cuts Price Target on Biogen to $277 From $295 Amid Alzheimer's Updates, Maintains S..
11/19BIOGEN INC. : Other Events, Financial Statements and Exhibits (form 8-K)
11/18BMO Capital Initiates Coverage of Biogen With Outperform Rating, $315 Price Target
11/18Biogen Inc. - Update on Regulatory Review of Aducanumab in the European Union
11/18Asian Stock Markets Wobble on Tech, Property Outlooks
11/18Nikkei 225 Off 0.3% Despite News on Government Stimulus Package
11/18Novartis Said Considering Takeover in Biotech Sector
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2021 10 878 M - -
Net income 2021 1 604 M - -
Net Debt 2021 2 311 M - -
P/E ratio 2021 22,7x
Yield 2021 -
Capitalization 35 680 M 35 680 M -
EV / Sales 2021 3,49x
EV / Sales 2022 3,26x
Nbr of Employees 9 100
Free-Float 85,5%
Duration : Period :
Biogen Inc. Technical Analysis Chart | BIIB | US09062X1037 | MarketScreener
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 32
Last Close Price 242,90 $
Average target price 351,89 $
Spread / Average Target 44,9%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Chairman
Alfred W. Sandrock Head-Research & Development
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors